RPRX Stock Summary and Trading Ideas (Royalty Pharma PLC - Class A | NASDAQ:RPRX)

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.

As of September 11, 2026, RPRX stock price declined to $58.61 with 2,387,051 million shares trading.

RPRX has a beta of 0.14, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.01 to the broad based SPY ETF.

RPRX has a market cap of $26.10 billion. This is considered a Large Cap stock.

Last quarter Royalty Pharma PLC - Class A reported $674 million in Revenue and $1.32 earnings per share. This fell short of revenue expectation by $-121 million and exceeded earnings estimates by $.05.

In the last 3 years, RPRX traded as high as $64.38 and as low as $24.05.

The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, VYM, CGDG, SCHM.

RPRX has outperformed the market in the last year with a return of +62.2%, while the SPY ETF gained +17.4%. In the last 3 month period, RPRX beat the market returning +6.4%, while SPY returned +3.9%. However, in the most recent 2 weeks RPRX has underperformed the stock market by returning -3.7%, while SPY returned -0.7%.

RPRX support price is $57.76 and resistance is $59.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.